Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$244.48
-$0.55(-0.40%)
At close: 4:00 PM EST
$244.48
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$160.86 - $250.74
Previous CloseN/A
Volume129.18K
Average Volume (3M)704.49K
Market Cap
$14.81B
Enterprise Value$12.91B
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)23.4
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume457,934
30 Day Avg. Volume704,487
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue14.88
Enterprise Value/Gross Profit16.88
Enterprise Value/Ebitda-1.86K
Forecast
1Y Price Target
$301.75Price Target Upside23.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)13.39
Revenue Forecast (FY)$1.34B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase two data showed the combination of the company's CNP therapy and added growth hormone produced sustained annualized growth and measurable improvements in arm span and spinal measurements, indicating broader clinical benefits beyond height gain.
Product Convenience And AdoptionRegulatory approval of Yuviwel for achondroplasia with once-weekly dosing and no food restrictions positions it as a more convenient alternative to the incumbent injectable and supports potential share gains with physicians and payors.
Regulatory PathwayCompletion of an end-of-phase-two meeting with regulators and a planned pivotal phase three study comparing the combination to monotherapy provides regulatory clarity that could reduce development risk and support higher valuation expectations.
Bears Say
Competitive ThreatAn oral competitor offering a more convenient dosing route could reduce uptake of injected therapies despite similar efficacy, putting pressure on market share for the company's injectables.
Label Limitations And Clinical SkepticismCurrent label restrictions limiting treatment to patients two years and older, along with expert doubts that the added growth hormone may provide only a short-lived boost, could narrow the addressable patient population and limit long-term adoption of the combination approach.
Payor Access And Pricing ImpactPayor access challenges for Skytrofa combined with expected gross-to-net discounts for Yorvipath are likely to constrain reported revenue even if prescription volumes remain strong.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $160.86 and its highest was $250.74 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $14.81B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on May 07, 2026. The company reported $11.356 earnings per share for the quarter, beating the consensus estimate of $0.189 by $11.167.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is 1.83.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 62,376,846 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of $11.356 in its last earnings report, beating expectations of $0.189. Following the earnings report the stock price went up 4.341%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$301.75 (23.43% Upside)
$301.75 (23.43% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 302.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.01%
12-Months-Change
Fundamentals
Return on Equity
-5641.90%
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$301.75
▲(23.43% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
<0.01% Insiders
11.60% Mutual Funds
― Other Institutional Investors
86.36% Public Companies and
Individual Investors